A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age >= 70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer

作者：Stinchcombe Thomas E^*; Peterman Amy H; Lee Carrie B; Moore Dominic T; Beaumont Jennifer L; Bradford Daniel S; Bakri Kamal; Taylor Mark; Crane Jeffrey M; Schwartz Garry; Hensing Thomas A; McElroy Edwin Jr; Niell Harvey B; Harper Harry D; Pal Sridhar; Socinski Mark A

来源：Journal of Thoracic Oncology, 2011, 6(9): 1569-1577.

DOI：10.1097/JTO.0b013e3182210430

• Quality of life
• Cumulative illness rating scale for geriatrics
• Targeted therapy
• Elderly

Introduction: Single-agent gemcitabine is a standard of care for elderly patients with advanced non-small cell lung cancer, but novel therapies are needed for this patient population.
Methods: We performed a noncomparative randomized phase II trial of gemcitabine, erlotinib, or the combination in elderly patients (age >= 70 years) with stage IIIB or IV non-small cell lung cancer. Patients were randomized to arms: A (gemcitabine 1200 mg/m(2) on days 1 and 8 every 21 days), B (erlotinib 150 mg daily), or C (gemcitabine 1000 mg/m(2) on days 1 and 8 every 21 days and erlotinib 100 mg daily). Arms B and C were considered investigational; the primary objective was 6-month progression-free survival.
Results: Between March 2006 and May 2010, 146 eligible patients received protocol therapy. The majority of the patients (82%) had stage IV disease, 64% reported adenocarcinoma histology, 90% reported current or previous tobacco use, and 28% had a performance status of 2. The 6-month progression-free survival rate observed in arms A, B, and C was 22% (95% confidence interval [CI] 11-35), 24% (95% CI 13-36), and 25% (95% CI 15-38), respectively; the median overall survival observed was 6.8 months (95% CI 4.8-8.5), 5.8 months (95% CI 3.0-8.3), and 5.6 months (95% CI 3.5-8.4), respectively. The rate of grade >= 3 hematological and nonhematological toxicity observed was similar in all three arms. The best overall health-related quality of life response did not differ between treatment arms.
Conclusions: Erlotinib or erlotinib and gemcitabine do not warrant further investigation in an unselected elderly patient population.

• 出版日期2011-9
• 单位西北大学